linezolid induced twice pure red cell aplasia in a patient with central nervous system infection after allogeneic stem cell transplantation
Authors
abstract
linezolid (lzd), severed as the first oxazolidinone antibiotic, was active against multidrug-resistant gram-positive strains. lzd can induce thrombocytopenia, anemia and leukocytopenia. currently, reports on pure red cell aplasia (prca) cases induced by lzd are relatively rare [4-7]. in this paper, we reported a patient with prca twice induced by lzd. a 37-year-old man was diagnosed with myelodysplatic syndrome (mds) and underwent allo-hsct from an unrelated donor with abo blood type- and leukocyte antigen (hla)-matching. after hsct for 2 years, the patient suffered from refractory fever and headache. he was first treated with empirical antifungal agent and antibiotics for central nervous system (cns) infection, but then changed to lzd therapy for little effect. twenty-eight days after lzd treatment, the symptom improved significantly but the hemoglobin declined to 70 g/l and the reticulocyte level was only 0.23%. the lzd therapy was stopped and the fever and headache symptoms reoccurred 1 week latter. then, erythropoietin (epo) and halved dosage of lzd were used for treatment. the cns infection and the anemia symptom relieved gradually and the level of hemoglobin and reticulocyte declined again. after blood transfusion, the half dose of lzd was sustained without anaemia recovery. in summary, patients with anemia, myelosuppressants history or potential abnormal proliferation of t cells may suffer prca with long term lzd treatment. the monitoring of complete blood count and reticulocyte count were necessary during lzd therapy. if the clinical condition permits, lzd dosage reduction and blood transfusion should be considered.
similar resources
Linezolid Induced Twice Pure Red Cell Aplasia in a Patient with Central Nervous System Infection after Allogeneic Stem Cell Transplantation
Linezolid (LZD), severed as the first oxazolidinone antibiotic, was active against multidrug-resistant gram-positive strains. LZD can induce thrombocytopenia, anemia and leukocytopenia. Currently, reports on pure red cell aplasia (PRCA) cases induced by LZD are relatively rare [4-7]. In this paper, we reported a patient with PRCA twice induced by LZD. A 37-year-old man was diagnosed with myelody...
full textLinezolid Induced Twice Pure Red Cell Aplasia in a Patient with Central Nervous System Infection after Allogeneic Stem Cell Transplantation
Linezolid (LZD), severed as the first oxazolidinone antibiotic, was active against multidrug-resistant gram-positive strains. LZD can induce thrombocytopenia, anemia and leukocytopenia. Currently, reports on pure red cell aplasia (PRCA) cases induced by LZD are relatively rare [4-7]. In this paper, we reported a patient with PRCA twice induced by LZD. A 37-year-old man was diagnosed with myelody...
full textLinezolid Induced Twice Pure Red Cell Aplasia in a Patient with Central Nervous System Infection after Allogeneic Stem Cell Transplantation
Linezolid (LZD), severed as the first oxazolidinone antibiotic, was active against multidrug-resistant gram-positive strains. LZD can induce thrombocytopenia, anemia and leukocytopenia. Currently, reports on pure red cell aplasia (PRCA) cases induced by LZD are relatively rare (4-7). In this paper, we reported a patient with PRCA twice induced by LZD. A 37-year-old man was diagnosed with myelody...
full textA patient with pure red cell aplasia after allogenic stem-cell transplantation. Parvo B19 infection.
full text
Pure Red Cell Aplasia due to B19 Parvovirus Infection after Autologous Stem Cell Transplantation
Parvovirus B19 is recognized as a rare cause of pure red cell aplasia (PRCA) in allogeneic stem cell (SCT) and solid organ transplant patients. We report a patient with Hodgkin's disease who developed PRCA due to parvovirus B19 after autologous SCT and who had an excellent response after treatment with gamma-globulin.
full textSuccessful Treatment of Pure Red Cell Aplasia with Rituximab in Patients after ABO-Compatible Allogeneic Hematopoietic Stem Cell Transplantation
Pure red cell aplasia (PRCA) following allogeneic hematopoietic stem cell transplantation (HSCT) has been mostly reported in situations involving major ABO incompatibility between donor and recipient. Conventional treatments such as plasma exchange, erythropoietin, and steroid are often unsatisfactory. Rituximab has been reported to be highly effective for PRCA following major ABO-incompatible ...
full textMy Resources
Save resource for easier access later
Journal title:
iranian journal of pharmaceutical researchجلد ۱۵، شماره ۲، صفحات ۶۴۷-۶۵۱
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023